Qure's long-term success hinges on overcoming regulatory and logistical challenges. See why I rate QURE stock a hold.

The good news? You don’t need to be a scientist to protect yourself from hype and heartbreak. So, HDBuzz has Ten Golden Rules ...

Shawn Kortes, known for his philanthropic work in the community, started dialysis this year and is searching for a kidney ...

AMT-130 is administered through magnetic resonance imaging-guided, convection-enhanced stereotactic neurosurgical delivery into the striatum.

Qure (NASDAQ:QURE) shares added ~39% in the premarket on Thursday after the Dutch biotech announced that the FDA granted ...

Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~~ ...

Roche gave an update this week about GENERATION HD2, testing the HTT-lowering drug tominersen in people with HD. The trial is ...

Gene therapy developer uniQure shares soared 46% in premarket trading after its treatment for Huntington's disease received breakthrough therapy designation from the Food and Drug Administration.

Shares of uniQure N.V. (NASDAQ:QURE) surged 39% following the announcement that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to AMT-130, its gene therapy ...

Qure (QURE) announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to AMT-130 for the treatment ...

Huntington’s Disease is a progressive neurodegenerative disorder that damages brain cells, which, in turn, affects movement, mood, and thinking. There are nearly 41,000 ...

The number of people who have the gene that causes Huntington's disease in Northern Scotland has been accurately counted for ...